Five years of improving diabetes control in Czech children after the establishment of the population‐based childhood diabetes register ČENDA

• Published in: Pediatric diabetes Vol. 21; no. 1; pp. 77 - 87
• Main Authors: Šumník, Zdeněk, Venháčová, Jitřenka, Škvor, Jaroslav, Pomahačová, Renata, Konečná, Petra, Neumann, David, Vosáhlo, Jan, Strnadel, Jiří, Čížek, Jindřich, Obermannová, Barbora, Petruželková, Lenka, Průhová, Štěpánka, Pavlíková, Markéta, Cinek, Ondřej
• Format: Journal Article
• Language: English
• Published: Former Munksgaard John Wiley & Sons A/S 01.02.2020; John Wiley & Sons, Inc
• Subjects: Adolescent; Child; Child, Preschool; Childhood; Children; Czech Republic - epidemiology; Diabetes; Diabetes mellitus (insulin dependent); Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 1 - diagnosis; Diabetes Mellitus, Type 1 - epidemiology; Diabetes Mellitus, Type 1 - therapy; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - epidemiology; Diabetes Mellitus, Type 2 - therapy; Female; Glucose; Glycated Hemoglobin A - metabolism; HbA1c; Hemoglobin; Humans; Hypoglycemic Agents - therapeutic use; Infant; Infant, Newborn; Insulin; Insulin - therapeutic use; Male; Patients; Pediatrics; register; Registries; Young Adult; Czech Republic; children; HbA1c; diabetes; register
• ISSN: 1399-543X; 1399-5448; 1399-5448
• DOI: 10.1111/pedi.12929

Objectives The Czech National Childhood Diabetes Register (ČENDA) is a web‐based nationwide database that collects treatment and outcome data in children and adolescents with diabetes. Here, we present data from the first 5 years of ČENDA (2013‐2017). Methods Data include characteristics of disease onset and annual summaries of key clinical care parameters from every patient treated by participating pediatric diabetes outpatient clinics. Results The database contains data of 4361 children (aged 0‐19 years) from 52 centers (85% of all Czech pediatric patients). Of these, 94% had type 1 diabetes (T1D), 4.5% had genetically proven monogenic or secondary, and 1.5% had type 2 diabetes. In children with T1D, median glycated hemoglobin (HbA1c) decreased throughout the observed period from 66.3 to 61.0 mmol/mol (P < .0001, 95% confidence interval [CI] for change −5.6 to −4 mmol/mol). Consequently, the proportion of children reaching the target therapeutic goal of 58.5 mmol/mol increased from 28% in 2013 to 40% in 2017. The proportion of children treated with insulin pumps (CSII) remained stable over the observed period (25%). In a subanalysis of 1602 patients (long‐standing T1D diagnosed before 2011), the main predictors associated with lower HbA1c were treatment with CSII, male sex and care provided at a large diabetes center (>100 patients). Conclusions A significant continuous decrease in HbA1c was observed in Czech children over the past 5 years. As this improvement was not accompanied by appreciable changes in the mode of therapy, we assume that the establishment of our nationwide register has itself constituted a stimulus towards improvement in the care process.